Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin. 

Patients with genital melanosis may need careful examinations for melanoma

2 months ago

A careful total body examination may be required in patients with genital melanosis, particularly those with any level of histologic atypia in the genital melanosis lesion, for the possibility of melanoma in any body site, according to a recent study.

To determine the potential risk for genital and nongenital melanoma in patients, a retrospective cohort study was conducted. The authors analysed clinical and histologic data from patients (n=41) with genital melanosis to better describe these lesions and the risk they confer for genital and nongenital melanoma.

Genital melanosis may clinically mimic melanoma, according to researchers. However, its typical age of onset is younger than for genital melanoma.

A majority of lesions stabilized or regressed over time. There were five patients found to have a history of melanoma, one of which was in the genital region. Lesions from these patients were more likely to show melanocytes with suprabasal movement (p=0.0101) and to have a higher melanocyte count (p<0.0462).

This study was limited by the relatively small cohort of patients with an average follow-up of only 30.5 months, researchers said.

A previous study had shown that reflectance confocal microscopy could noninvasively differentiate between vulvar melanoma and vulvar melanosis. Two major features were identified with vulvar melanosis: papillae rimmed by bright monomorphous cells and possible presence of a few dendritic bright cells in the basal layer of the epithelium. Vulvar melanoma was also associated with two major characteristics: atypical cells in the epithelium and loss of normal architecture of chorion papillae. [Dermatol Surg 2012;38:1962-7]

Editor's Recommendations
Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.